These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31842697)

  • 1. Discovery of selective farnesoid X receptor agonists for the treatment of hyperlipidemia from traditional Chinese medicine based on virtual screening and in vitro validation.
    Chen X; Lu F; Luo G; Ren Y; Ma J; Zhang Y
    J Biomol Struct Dyn; 2020 Sep; 38(15):4461-4470. PubMed ID: 31842697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
    Sindhu T; Srinivasan P
    Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel farnesoid X receptor agonist, kaempferol-7-O-rhamnoside, a compound ameliorating drug-induced liver injury based on virtual screening and in vitro validation.
    Liu K; Chen X; Ren Y; Liu C; Yuan A; Zheng L; Li B; Zhang Y
    Toxicol Appl Pharmacol; 2022 Nov; 454():116251. PubMed ID: 36150480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders.
    Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A
    Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
    Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
    Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
    De Marino S; Festa C; Sepe V; Zampella A
    Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
    Marchianò S; Biagioli M; Bordoni M; Morretta E; Di Giorgio C; Vellecco V; Roselli R; Bellini R; Massa C; Cari L; Urbani G; Ricci P; Monti MC; Giordano A; Brancaleone V; Bucci M; Zampella A; Distrutti E; Cieri E; Cirino G; Fiorucci S
    J Am Heart Assoc; 2023 Dec; 12(23):e031241. PubMed ID: 37996988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of 12β-methyl-17-epi-18-nor-bile acids as potent and selective TGR5 agonists.
    Luxenburger A; Harris LD; Ure EM; Jiao W; Woolhouse AD; Cameron SA; Weymouth-Wilson A; Furneaux RH; Pitman JL; Hinkley SFR
    Eur J Med Chem; 2023 Mar; 250():115143. PubMed ID: 36841086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
    Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
    Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells.
    Stefela A; Kaspar M; Drastik M; Kronenberger T; Micuda S; Dracinsky M; Klepetarova B; Kudova E; Pavek P
    Front Pharmacol; 2021; 12():713149. PubMed ID: 34483922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists.
    Miyata S; Kawashima Y; Sakai M; Matsubayashi M; Motoki K; Miyajima Y; Watanabe Y; Chikamatsu N; Taniguchi T; Tokuyama R
    Sci Rep; 2021 Apr; 11(1):9196. PubMed ID: 33911126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists.
    Zhao S; Peng W; Li X; Wang L; Yin W; Wang YD; Hou R; Chen WD
    RSC Adv; 2021 Jan; 11(4):2158-2166. PubMed ID: 35424145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators.
    Di Leva FS; Di Marino D; Limongelli V
    Handb Exp Pharmacol; 2019; 256():111-136. PubMed ID: 31161298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor.
    Jiang L; Liu X; Wei H; Dai S; Qu L; Chen X; Guo M; Chen Y
    Biochem Biophys Res Commun; 2022 Mar; 595():1-6. PubMed ID: 35091108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Discovery of potential LXRβ agonists from Chinese herbs using molecular simulation methods].
    Luo GG; Lu F; Qiao LS; Li Y; Zhang YL
    Zhongguo Zhong Yao Za Zhi; 2016 Aug; 41(16):3065-3071. PubMed ID: 28920350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pharmacology of Bile Acids and Their Receptors.
    Fiorucci S; Distrutti E
    Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH.
    Marchianò S; Biagioli M; Morretta E; Di Giorgio C; Roselli R; Bordoni M; Bellini R; Urbani G; Massa C; Monti MC; Zampella A; Distrutti E; Fiorucci S
    Sci Rep; 2023 Jan; 13(1):1602. PubMed ID: 36709356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.